中文摘要
一般而言，傳統施打疫苗的方法是指進行首次疫苗注射後，再以同樣的疫苗進行
追加注射，稱為homologous prime-boost 免疫法。但在這裡我們要介紹的heterologous prime-boost 免疫法與傳統免疫法不同的地方在於首次注射與追加劑使用的不是相同的疫苗。近來heterologous prime-boost免疫法透過臨床實驗證實能增強宿主的免疫反應並發表在HIV-1疫苗的研究文獻上，顯示這是一個值得去探討的新免疫法。
近年來，重組腺病毒載體廣泛應用於疫苗傳遞系統並且成功的引起宿主免疫反應，包含體液免疫與細胞免疫反應，於是我們利用重組腺病毒載體表現高致病力的禽流感病毒(H5N1)表面的血球凝集素，並以其與重組血球凝集素蛋白的組合進行免疫實驗，探究老鼠身上所引發的免疫反應。除此之外，我們也使用DNA載體與DNA和重組蛋白的組合進行免疫當作控制組，觀察不同的prime-boost免疫法是否比同樣的prime-boost免疫法的效果來得好。結果顯示，利用腺病毒載體與蛋白組合的heterologous prime-boost免疫組與進行homologous prime-boost以及DNA的免疫組相比，免疫反應的確有顯著增強。所以我們認為，使用腺病毒比DNA所引起的免疫效果較好，且腺病毒與蛋白組合的免疫法比起其他組具有較強的免疫反應，顯示此種heterologous prime-boost免疫法值得進行探究，並期望能應用於未來流感疫苗的研發。

References

Amara RR, Villinger F, Altman JD, Lydy SL, O’Neil SP, Staprans SI, Montefiori DC, Xu Y, Herndon JG, Wyatt LS et al. 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292:69-74.

Aparicio, O., N. Razquin, M. Zaratiegui, I. i. Narvaiza, and P. Fortes. 2006. Adenovirus
Virus-Associated RNA Is Processed to Functional Interfering RNAs Involved in Virus
Production. JOURNAL OF VIROLOGY 80:1376–1384.

Bangari, DS and Mittal, SK. 2006. Development of nonhuman adenoviruses as vaccine vectors. Vaccine 24: 849–862.

Buchbinder SP, Mehrotra DV, Duerr A, et al. 2008. Efficacy assessment of a cell-mediated
immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881–1893.

Catanzaro, A. T., R. A. Koup, M. Roederer, R. T. Bailer, M. E.Enama, Z. Moodie, L.Gu,
J. E. Martin, L. Novik, B. K. Chakrabarti, B. T. Butman, J. G. D. Gall, C. R. King,
C. A. Andrews, R. Sheets, P. L. Gomez, J. R. Mascola, G. J. Nabel, B. S. Graham,
and t. V. R. C. S. Team. 2006. Phase 1 Safety and Immunogenicity Evaluation of a
Multiclade HIV-1 Candidate Vaccine Delivered by a Replication-Defective Recombinant
Adenovirus Vector. J Infect Dis. 194:1638–1649.

Demberg, T., R. H. Florese, M. J. Heath, K. Larsen, I. Kalisz, V. S. Kalyanaraman,
E. M. Lee, R. Pal, D. Venzon, R. Grant, L. J. Patterson, B. Korioth-Schmitz, A.
Buzby, D. Dombagoda, D. C. Montefiori, N. L. Letvin, A. Cafaro, B. Ensoli, and M.
Robert-Guroff. 2007. A Replication-Competent Adenovirus-Human Immunodeficiency
Virus (Ad-HIV) tat and Ad-HIV env Priming/Tat and Envelope Protein Boosting
Regimen Elicits Enhanced Protective Efficacy against Simian/Human Immunodeficiency
Virus SHIV89.6P Challenge in Rhesus Macaques. JOURNAL OF VIROLOGY
81:3414-3427.

Dormond, E., M. Perrier, and A. Kamen. 2009. From the first to the third generation
adenoviral vector: What parameters are governing the production yield? Biotechnology
Advances 27:133-144.

Emily Rumschlag-Booms, Ying Guo, Jizhen Wang, M. Caffrey, and L. Rong. 2009.
Comparative analysis between a low pathogenic and a high pathogenic influenza H5
hemagglutinin in cell entry. Virology Journal 6:76.

Ellebedy, A. H., and R. J. Webby. 2009. Influenza vaccines. Vaccine 27:D65–D68.

Gao W, Soloff AC, Lu X, Montecalvo A, Nguyen DC, Matsuoka Y, Robbins PD, Swayne DE, Donis RO, Katz JM, Barratt-Boyes SM, Gambotto A. 2006. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 80 : 1959-1964.

Gómez-Román, V. R., and M. Robert-Guroff. 2003. Adenoviruses as Vectors for HIV
Vaccines. AIDS Rev 5:178-185.

Guo, L., H. Zhou, MinWang, J. Song, B. Han, Y. Shu, L. Ren, H. Si, J. Qu, Z. Zhao, J. Wang, and T. Hunga. 2009. A recombinant adenovirus prime-virus-like particle boost regimen elicits effective and specific immunities against norovirus in mice. Vaccine 27:5233-5238

Hartman, Z. C., D. M. Appledorn, and A. Amalfitano. 2008. Adenovirus vector induced
innate immune responses: Impact upon efficacy and toxicity in gene therapy and vaccine
applications. Virus Research 132:1-14.

Haynes, J.R., Dokken, L., Wiley, J.A., Cawthon, A.G., Bigger, J., Harmsen, A.G., Richardson C. 2009. Influenza-pseudotyped Gag virus-like particle vaccines provide
broad protection against highly pathogenic avian influenza challenge. Vaccine
27: 530–541.

Hoelscher, M. A., N. Singh, S. Garg, L. Jayashankar, Vic Veguilla, A. Pandey, Y.
Matsuoka, J. M. Katz, R. Donis, Suresh K. Mittal, and S. Sambhara. 2008. A Broadly
Protective Vaccine against Globally Dispersed Clade 1 and Clade 2 H5N1 Influenza
Viruses. J Infect Dis. 197:1185-1188.

Hu SL, Klaniecki J, Dykers T, Sridhar P, Travis BM. 1991. Neutralizing antibodies against HIV-1 BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 (BRU) envelope glycoproteins and boosted with homologous gp160. AIDS Res Hum Retroviruses 7:615-620.

Hu SL, Abrams K, Barber GN, Moran P, Zarling JM, Langlois AJ, Kuller L, Morton WR, Benveniste RE. 1992. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255:456-459.

Imler, J.-L. 1995. Adenovirus vectors as recombinant viral vaccines. Vaccine 13:1143-1151.

J. H. C. M. Kreijtz, Y. Suezer, G. de Mutsert, J. M. A. van den Brand, G. van
Amerongen, B. S. Schnierle, T. Kuiken, R. A. M. Fouchier, J. Löwer,
A. D. M. E. Osterhaus, G. Sutter, and G. F. Rimmelzwaan. 2009. Recombinant
Modified Vaccinia Virus Ankara Expressing the Hemagglutinin Gene Confers
Protection against Homologous and Heterologous H5N1 Influenza Virus Infections in
Macaques. The Journal of Infectious Diseases 199.

Kim, J. H., and J. Jacob. 2009. DNA Vaccines Against Influenza Viruses. Current Topics in
Microbiology and Immunology 333.

Khanam, S., P. Rajendra, N. Khanna, and S. Swaminathan. 2007. An adenovirus
prime/plasmid boost strategy for induction of equipotent immune responses to two
dengue virus serotypes. BMC Biotechnology 7.

Lasaro, M. O., and H. C. Ertl. 2009. New Insights on Adenovirus as Vaccine Vectors.
Molecular Therapy 17.

Li Xing and Suresh K Tikoo. 2009. Packaging of viral RNAs in virions of adenoviruses. Virol J. 6: 16.

Li, B.-W., A. Rush, S. R. Zhang, K. C. Curtis, and G. J. Weil. 2004. Antibody responses to
Brugia malayi antigens induced by DNA vaccination. Filaria Journal 3.

Lu, S. 2009. Heterologous prime–boost vaccination. Current Opinion in Immunology
21:346-351.

Magalhaes I, Sizemore DR, Ahmed RK, Mueller S, Wehlin L, et al. 2008. rBCG Induces Strong Antigen-Specific T Cell Responses in Rhesus Macaques in a Prime-Boost Setting with an Adenovirus 35 Tuberculosis Vaccine Vector. PLoS ONE 3(11): e3790

McHardy, A. C., and B. Adams. 2009. The Role of Genomics in Tracking the Evolution of
Influenza A Virus. PLoS Pathogens 5.

Morris, S. J., and K. N. Leppard. 2009. Adenovirus serotype 5 L4-22K and L4-33K
proteins have distinct functions in regulating late gene expression. J. Virol.

Price GE, Soboleski MR, Lo CY, Misplon JA, Pappas C, Houser KV, Tumpey TM, Epstein SL. 2009. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 27: 6512–6521

Rowe WP, Huebner RJ, Gilmore LK, Parrott RH, Ward TG. 1953. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med 84(3):570–3.

Russell W. C. 2000. Update on adenovirus and its vectors. J Gen Virol. 81:2573–2604.

Russell W. C. 2009. Adenoviruses: update on structure and function. Journal of General
Virology 90:1-20.

Schenk TE. 2001. Adenoviridae the viruses and their replication. In: Knipe DM, Howley PM, editors. Fundamental Virology. Lippincott Williams & Wilkins ed. p. 979-1016.

Schepp-Berglind, J., M. Luo, D. Wang, J. A. Wicker, N. U. Raja, B. D. Hoel, D. H.
Holman, A. D. T. Barrett, and J. Y. Dong. 2007. Complex Adenovirus-Mediated
Expression of West Nile Virus C, PreM, E, and NS1 Proteins Induces both Humoral and
Cellular Immune Responses. Clinical and vaccine immunology 14: 1117–1126.

Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA et al. 2002. Replication-incompetent adenoviral vaccine vector elicits effective antiimmunodeficiency-virus immunity. Nature 415:331-335.

Shi Z, Zeng M, Yang G, et al. 2001. Protection against tetanus by needle-free inoculation of
adenovirus vectored nasal and epicutaneous vaccines. J. Virol 75:11474–11482.

Shott, J. P., Shannon M. McGratha, Maria Grazia Paub, Jerome H.V. Custersb, Olga
Ophorst , M.-A. Demoitie´, M.-C. Dubois, J. Komisar, M. Cobba, Kent E. Kestera,
Patrice Duboisc, J. Cohenc, Jaap Goudsmitb, D. Gray Heppnera, and V. A. S. 2008.
Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite
surface protein elicit potent antigen-specific cellular IFN-_ and antibody responses in
mice. Vaccine 26:2818-2823.

Supachai Rerks-Ngarm, M. D. Punnee Pitisuttithum, M. D. Sorachai Nitayaphan, Ph.D.,
P. D. Jaranit Kaewkungwal, M. D. Joseph Chiu, M. D. Robert Paris, M. D. Nakorn
Premsri, M. D. Chawetsan Namwat, P. D. Mark de Souza, M. D. Elizabeth Adams,
M. D. Michael Benenson, M. D. Sanjay Gurunathan, P. D. Jim Tartaglia, M. D.
John G. McNeil, M. D. Donald P. Francis, P. D. Donald Stablein, M. D. Deborah L.
Birx, M. D. Supamit Chunsuttiwat, M. D. Chirasak Khamboonruang, M. D. Prasert
Thongcharoen, Ph.D.,, M. D. Merlin L. Robb, M. D. Nelson L. Michael, Ph.D., , M.
D. Prayura Kunasol, and M. D. Jerome H. Kim. 2009. Vaccination with ALVAC and
AIDSVAX to Prevent HIV-1 Infection in Thailand. The new england journal of
medicine 361.

Tatsis, N and Ertl, HC. 2004. Adenoviruses as vaccine vectors. Mol Ther 10: 616–629.

Tang, D.-c. C., J. Zhang, H. Toro, Z. Shi, and K. R. V. Kampen. 2009. Adenovirus as a
carrier for the development of influenza virus-free avian influenza vaccines. Expert Rev Vaccines 8:469-481.

Uyeki, TM. 2008. Global epidemiology of human infections with highly pathogenic avian influenza A (H5N1) viruses. Respirology 13:s1, S2-S9.

Uhl EW, Harvey SB, Michel F, Perozo Y, Gabbard J, Tompkins SM, Hogan RJ. 2010. Immunogenicity of avian H5N1 influenza virus recombinant vaccines in cats. Viral Immunology 23:221-6.

Vaine M, Wang S, Crooks ET, Jiang P, Montefiori DC, Binley J, Lu S. 2008. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J Virol 82:7369-7378.

Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, Shen S, Liu Q, Whitney S, Keen T, Nair BC et al. 2006. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 350:34-47.

Wang S, Parker C, Taaffe J, Solorzano A, Garcia-Sastre A, Lu S. 2008. Heterologous HA DNA vaccine prime—inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine 26:3626-3633.